The country accounted for a third of the market across Asia Pacific.
Minimally invasive neurosurgical procedures in Japan have been either delayed or deferred due to the ongoing COVID-19 pandemic, but the market is expected to rebound over the next five years as the government has eased lockdown measures hence some of the elective procedures have been resumed, according to a report from GlobalData.
Japan’s minimally invasive neurosurgical devices accounted for 33% of the Asia-Pacific market in 2020. These are expected to grow in the next five years, driven by the growing incidence of stroke, intracerebral hemorrhage, and technological advancements in diagnostics.
“With easing of lockdown measures, elective neurosurgical procedures are expected to resume at a higher rate. In addition, the availability of COVID-19 vaccine is expected to lead to further growth in the elective neurosurgical procedure volumes,” GlobalData’s medical devices anlayst Anusha Kaushik said.
Further, as more clinical trial results are released confirming the benefits of minimally invasive neurosurgery, GlobalData expects that their use will become more standard as more guidelines are built and more specialists become comfortable with the technique.
The aspiration irrigation system disposable handpieces accounted for about 80% of the minimally invasive neurosurgical devices market in Japan in 2020.
Do you know more about this story? Contact us anonymously through this link.